ERBB2 and breast carcinoma: EndoPredict Test, offered by Myriad Genetics, Inc. and available in the US since 2017, is a genomic test for newly diagnosed patients with early-stage, ER-positive, HER2-negative breast cancer (lymph node-negative or node-positive (1–3 nodes), pre- or postmenopausal).